Stocks and Investing
Stocks and Investing
Tue, May 28, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, May 24, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, May 23, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Terence Flynn Initiated (BPMC) at Strong Buy and Held Target at $125 on, May 23rd, 2019
Terence Flynn of Goldman Sachs, Initiated "Blueprint Medicines Corporation" (BPMC) at Strong Buy and Held Target at $125 on, May 23rd, 2019.
Terence has made no other calls on BPMC in the last 4 months.
There is 1 other peer that has a rating on BPMC. Out of the 1 peers that are also analyzing BPMC, 0 agree with Terence's Rating of Hold.
This is the rating of the analyst that currently disagrees with Terence
- Andrew Berens of "Morgan Stanley" Initiated at Buy and Held Target at $112 on, Wednesday, April 3rd, 2019